{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-25-000098","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.021423+00:00","generated_at":"2026-05-17T17:22:24.189841+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cartesian Therapeutics reports Q2 net income $15.9M; initiates Phase 3 AURORA trial for Descartes-08 in MG","bullets":["Cash, equivalents and restricted cash $162.1M as of June 30, 2025; expected to fund operations into mid-2027.","Net income $15.9M ($0.51 basic EPS) vs $13.8M ($0.58 basic EPS) in Q2 2024.","R&D expenses $14.9M, up from $12.7M, driven by Phase 3 AURORA trial costs.","Preliminary Phase 2 data for Descartes-08 in SLE expected in 2H25; pediatric basket trial initiation also expected in 2H25.","Phase 3 AURORA trial of Descartes-08 in myasthenia gravis dosed first participant in May 2025; primary endpoint at Month 4."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-25-000098","json":"https://secwatch.observer/filing/0001453687-25-000098.json","markdown":"https://secwatch.observer/filing/0001453687-25-000098.md","text":"https://secwatch.observer/filing/0001453687-25-000098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000098/0001453687-25-000098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000098/rnac-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:22:24.189841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}